Dr. David Spigel, Sarah Cannon Cancer Center, offers his perspective on the agents he feels most likely to become clinical tools against lung cancer over the next few years.
Dr. David Spigel, Sarah Cannon Cancer Center, offers his perspective on the agents he feels most likely to become clinical tools against lung cancer over the next few years.
read more
read less
10 years ago
#afatinib, #alk, #cancer, #cancergrace, #cannon, #center, #david, #egfr, #grace, #gracecast, #immunotherapy, #inhibitor, #kras, #ldk, #mek, #met, #pd1, #pdl1, #sarah, #spigel
